Index

3 by 5 initiative, 83

AbiCor artificial heart, 342–4
adjuvant, 199
administrative costs, 141–2
aging population, 136–7
AIDS, 79–85, 96–8, 105, 215
AIDSVAX, 218
anastamosis, 333
angina, 91–2, 327
angiogenesis, 258
angioplasty, 331–3, 334–5
antibiotic resistance, 67
antibody, 194–5
antigenic drift, 196
antigenic shift, 196, 210
antiviral drugs, 197
apheresis, 11, 12
Apligraf, 176
artemisinin, 75
artificial heart, 340
ARVs, 24, 27
assessment, 306
association, 39
atherosclerosis, 91, 171, 329, 334–5
avian flu, 198

Bacille Calmette Guerin (BCG), 96
bacteria, 187, 188
bacterial disease, 189
basophils, 187
B-cells, 199
BD SoloShot syringe, 214
bed net, insecticide treated, 75
Belmont Report, 232, 233–5, 378
bile, 369, 377
bioinstrumentation, 161, 162–9
Biojector2000, 214
biomaterials, 4, 172–4
biomechanics, 4, 169–72
biomedical engineering, 4, 152–3
biomedical imaging, 4, 153–62
biopsy, 285, 288–98
biosensors, 4, 161, 162–9
biosystems engineering, 4
birth asphyxia, 62
birth trauma, 62
blinded seroprevalence studies, 236–7
blood pressure, 324
bone marrow transplant, 11–16
brain–machine interface, 164

CA-125 blood test, 292, 293–4
cancer, 99–102, 104
  cancer, breast cancer, 5–11, 13, 21, 169
  cancer, burden, 248, 250
  cancer, cervical cancer, 267, 268–81
  cancer, early detection, 259
  cancer, lung cancer, 104
  cancer, mortality, 250–3
  cancer, ovarian cancer, 285, 288–98
  cancer, pain, 263–4
  cancer, pathophysiology of cancer, 254
  cancer, prostate, 25, 281–8
  cancer, risk, 253–4
  cancer, screening, 260
cardiac output, 325
cardiovascular disease, 90–4, 104, 320–49
cardiovascular disease, prevention, 347–9
CD4 lymphocytes, 80, 82, 215
cellular engineering, 178–81
cerebrovascular disease (stroke), 91, 93–4, 322
cervix, 268
chemotherapy, 10–11
childhood deaths, 77
chloroquine, 75
cholera, 32, 71–2
cirrhosis, 105, 106
clinical practice, 232
clinical trials, 14, 21, 23, 356–66
clinical trials, drugs, 361
Clinton plan, 145
clonal expansion, 195
cold chain, 212–13
colpcoscope, 161, 162–9

© in this web service Cambridge University Press

CAMBRIDGE

Cambridge University Press
978-0-521-87797-8 - Biomedical Engineering for Global Health
Rebecca Richards-Kortum
Index
More information

colposcopy, 272–3
columnar epithelial cells, 269
computer axial tomography (CT), 94, 157
congenital anomalies, 75–6
coronary arteriography (cardiac catheterization), 92, 93
coronary artery bypass grafting (CABG), 92, 328–31, 334–5
coronaviruses, 64
crash test, 89

data
  data, collection, 27
  data, economic data, 40–3
  data, health data, 32–40
  data, primary data, 27
  data, secondary data, 27
Data Safety and Monitoring Boards (DSMB), 363
Da Vinci robotically assisted coronary surgery system, 332
decision analysis, 24, 27
Declaration of Helsinki, 232
dehydration, 70–3
descriptive statistics, 358
design specification, 152
Device Amendments to FD&C Act, 383–4, 385
diagnosis, 25
diarrheal disease, 67–74
diastole, 323
Dietary Supplement Health Education Act (DSHEA), 381–3, 385
dietary supplements, 369, 376–8, 381–3
digestive diseases, 105–6
digital image analysis (DIA), 278
diptheria, 202
direct immunofluorescence assays (DFA), 65, 66
direct visual inspection with acetic acid, 315–16
directly observed treatment short-course (DOTS), 98
disability adjusted life years (DALY), 37, 106
discounted life expectancy, 315
Don Thomas, 11
Drug Amendments Act, 380, 385
drug delivery, 172–4

echocardiography, 326
economic evaluation, 305–10
edema, 336
edible vaccines, 201
effect size, 362
effectiveness, 26, 308
efficacy, 26
ejection fraction, 325
electrocardiagram, 92
engineering design, 151–2
enzyme-linked immunosorbents assays (ELISA), 65, 81, 82
eosinophils, 187
Ephedra, 369, 377
epidemiologist, 32
epidermal growth factor receptor (EGFR), 181
epithelial tissue, 269
epithelium, 254
experimental approach, 360

FDA, 203, 376–91
fetal alcohol syndrome, 76
fetal ultrasound, 61
flow cytometer, 165–6
folate deficiency, 76
Food Drug and Cosmetic Act, 380, 385
Freireich, Emil J., 119–21, 170–1
fusion inhibitors, 83

gall bladder, 369, 376–8
Gallo, Robert, 215
gallstones, 369
Gates Foundation, 107
Global Alliance for Vaccines and Immunization (GAVI), 214
global burden of disease, 55
Global Outbreak Alert and Action, 35
glucose-sodium transporter, 71

HDCT + BMT, 13–17, 21, 23–4
health expenditure, 136
Health Maintenance Organization (HMO), 121, 175
health-policy space, 306
health systems, 113, 115, 119
  health systems, centrally planned economy, 127
  health systems, comprehensive health system, 77, 115
  health systems, entrepreneurial health system, 115
  health systems, free market economy, 128–31
  health systems, single payer system, 121–4
  health systems, socialist health system, 115, 125–7
  health systems, US health system, 119–21, 170–1
  health systems, welfare-oriented health system, 115
healthcare reform, 143–6
heart attack, 92, 326–8
heart attack treatment, 328
heart failure, 335–7
  heart failure, left ventricle, 336
  heart failure, right ventricle, 337
  heart failure, treatment, 337–8
heart rate, 325
heart transplant, 338–40
heart–lung machine, 155–6, 331
HeartMate III, 342, 348
Heckler, Margaret, 215
Helsinki Declaration, 234
hepatitis, 105
herd immunity, 204
high density lipoprotein (HDL), 323
highly active anti-retroviral therapy (HAART), 82–3
Hippocratic Oath, 234
histocompatibility markers, 12
HIV, human immunodeficiency virus, 28, 79–85, 105
  HIV, prevention, 237–9
  HIV, screening, 81
  HIV, testing, 217
  HIV, transmission, 237
  HIV, vaccine, 215–22
  HIV, vaccine, live attenuated, 220
  HIV, vaccine, noninfectious, 218–20
  HIV virus, 191
  HIV, HIV-1, 218
  HIV, HIV-2, 218
HPV, human papillomavirus, 270–1
  HPV, DNA testing, 277, 278, 313–16
  HPV, vaccine, 279
human development index (HDI), 41
hyperlipidemia, 91
hypernatremia, 73

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-87797-8 - Biomedical Engineering for Global Health
Rebecca Richards-Kortum
Index
More information

hypertension, 91, 323
hypothesis, 151
  hypothesis, generation, 358–60
  hypothesis, testing, 360–1

immune system, 187, 198
  immune system, adaptive immune system, 192, 194, 198
  immune system, antibody-mediated immunity, 198
  immune system, cell-mediated immunity, 194, 198
  immune system, humoral immunity, 194
  immune system, innate immune system, 192–4, 198
  immune system, physical barrier, 192, 198
immunization, 202–3
immunoassay, 167–8
immunosuppressive drugs, 338
incidence, 34
infectious disease, 186–98
influenza, 190, 196–8
  influenza, vaccine, 206, 209–11
Institute of Medicine (IOM), 29
Institutional Review Board (IRB), 235
International Health Regulations (IHR), 35
investigational new drug (IND), 378
iodine deficiency, 76
ischemia, 91
ischemic heart disease, 90–1, 93, 322

Jarvik-7 artificial heart, 342, 348
Jenner, Edward, 200–1
Jewish Chronic Disease Hospital Study, 231–2
jungle, the, 232, 378

Kaposi's sarcoma, 33, 80, 81
Karp, Haskell, 341
King, Albert, 90–1

lab-on-a-chip, 166
Langer, Robert, 121, 175
laproscopic cholecystectomy, 371–2
lead-time bias, 281–4, 287
least developed country, 43
left ventricular assist devices, 344–7
liquid cytology, 275–6, 313–16
Littenberg, Benjamin, 22–4
low density lipoprotein (LDL), 323
lower respiratory infections, 63–7
low-income country, 42
lumpectomy, 10
lymphocytes, 187
  lymphocytes, T-lymphocytes, 195

macrophage, 193
magnetic resonance imagin (MRI), 94, 157–8
major histocompatibility (MHC) complex, 195
malaria, 74–5
  malaria, cerebral malaria, 75
mammography, 9, 267
Mantoux tuberculin skin test (purified protein derivative test), 96
mastectomy, 10
master console, 332
Medicaid, 119
medical device classification, 384
Medicare, 119
metastasis, 101
metastatic tumor, 258
methylmercury, 76
microfluidics
middle-income country, 42
minimum clinically important difference, 363
MMR vaccine, 204–5
molecular engineering, 178–81
monocytes, 187
morbidity, 37, 106–7
Morbidity and Mortality Weekly Report (MMWR)
mortality, 37, 55–7, 106–7
  mortality rate, 37
  15–44 years, 79–104
  45–60 years, 104–6
  birth–4 years, 57–79
  infant, 37, 77–9
  neonatal, 77
mother to child transmission, 85
MR angiography (MRA), 94
multi-drug resistant TB (MDR TB), 98
mutation, HIV, 197, 217–18
myocardial infarction, 92

nationally notifiable diseases, 34, 36
National Institutes of Health, 390–1
needle-free vaccine, 214
negative predicitive value, 266–8
neonatal period, 57
neutrophils, 187
new drug application (NDA), 378
NIH, 390
nuclear to cytoplasmic ratio (N/C ratio), 256
Nuremberg Code, 232, 234, 235

observational study, 360
oncogenic mutation, 257
open heart surgery, 328–31
optical microscope, 161–2
oral rehydration therapy, 70–3

Pap smear, automated, 276–7
Pap smear, Papanicoloau, 271–2, 273–5, 313–16
partograph, 63
Pasteur, Louis, 201
PATH, 63
pattern discovery, 296
per capita health expenditure, 40
per capita income, 39, 40
percutaneous transluminal coronary angioplasty (PTCA), 92
perinatal conditions, 60–3
perinatal period, 57
perspective, 308
pertussis, 64, 189, 190
PET, 158–60
physiology, 178
plaque, 92
plasma, 10
Plasmodium falciparum, 74
platelets, 10
Pneumocystis carinii pneumonia (PCP), 33, 80, 81
pneumonia, 64–7
  pneumonia, bacterial, 64
  pneumonia, viral, 64
point of service (POS), 121, 205–12
point prevalence, 35
polio, 202
positive predictive value, 266–8
pre-cancerous lesions, 256

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-87797-8 - Biomedical Engineering for Global Health
Rebecca Richards-Kortum
Index
More information

preferred provider organization (PPO), 121
premature birth, 79
prescription drug costs, 137–8
prevalence, 35, 267, 268–81
prevention, 25
primary tumor, 258
priority rating, 143
prostate specific antigen (PSA), 284
prostatectomy, 285, 292–3
protease inhibitors, 82
purchasing power parity (PPP), 40
Pure Food and Drug Act, 378, 385

quality adjusted years of life (QALYs), 113, 306, 308
QuantiFERON-TB Gold (QFT-G) blood serum test, 96
quinine, 75

red blood cells, 10
regenerative medicine, 175–7
regulation of healthcare technologies, 376–91
rehabilitation, 25
rejection rates, 338–9
relative risk, 39, 40
research, 235
resistance, 83
resistant strains of bacteria, 67
restenosis, 174, 333
reverse transcriptase, 82
road traffic accidents, 85
RotaShield, 73
rotavirus, 67, 73–4
rubella, 76, 202

sample size, 361–6
San Antonio Contraceptive Study, 232
scientific method, 150–1
scientific misconduct, 16
screening, 25
scurvy, 368
self-inflicted injuries, 102–4
Semm, Kurt, 373–4
sensitivity, 264, 265–6
sensitivity analysis, 309
sepsis, 63
serum PSA test, 283
severe acute respiratory syndrome (SARS), 64
smallpox, 200–1, 202
smoking, 91
Snow, John, 32
sodium reabsorption, 70–3
specificity, 264, 265–6
sphygmomanometer, 324
squamous epithelial cells, 269
standard deviation, 358–60
standard of care, 26, 239–40
standardized sifference, 361, 362
Starling's Law, 336
State Children's Health Insurance Program (SCHIP), 119
stem cells, 11
stent, 172, 174, 333, 334–5
stent, drug eluting, 333
stroke, 93–4
  ischemic stroke, 93
stroke volume, 325
suicide, 102
surgical cart, 332
syphilis, 231
systems biology, 178
systole, 323

technology assessment, 17, 21–2, 24–6, 29, 305
technology development, 4–5
technology diffusion, 368–75
technology utilization, 138–9
thalidomide, 33, 76, 380
ThinPrep, 275
thrombolysis, 94
tissue engineering, 175–7
training phase, 296
transcutaneous energy transmission, 343
transient ischemic attack, 93–4
treatment, 25
tuberculosis, 94–9
tumor
  tumor, benign, 99
  tumor, malignant, 99
Tuskegee Syphilis Study, 229–31, 235
type I error, 361
type II error, 361, 362

ultrasound, 160–1
ultrasound imaging, 285, 292–3
Unicef, 72
uninsured, 142–3
unintentional injuries, 77, 85, 104–5

vaccination in developing countries, 212–15
vaccine, 199
  vaccine, bivalent, 207
  vaccine, carrier, 220
  vaccine, DNA, 220
  vaccine, inactivated organism vaccine, 199
  vaccine, live attenuated vaccine, 199–200
  vaccine, monovalent, 207
  vaccine potency, 212
  vaccine production, 121, 205–12
  vaccine, subunit vaccine, 200
vaccine vial monitors (VVM), 213
variance, 358
Vioxx, 386–8
viral disease, 190
viral load, 80, 83
  viral load, tests, 84
virus, 188
visual inspection with acetic acid (VIA), 277–8

Weekly Epidemiological Record, 34, 36
white blood cells, 10, 187
WHO, 32, 66, 72
Willowbrook Study, 231
World Food Programme (WFP), 39, 56–7
World Health Report, 34

X-ray, 157

© in this web service Cambridge University Press www.cambridge.org